{"title":"托瑞米芬治疗子宫癌的II期研究。初步的沟通","authors":"G. Horváth, C. Tropé, H.-E. Almbo","doi":"10.1016/0022-4731(90)90017-M","DOIUrl":null,"url":null,"abstract":"<div><p>A phase II study of toremifene was started in patients suffering from advanced carcinoma corporis uteri. Minimum duration of treatment was 3 months but with stabilized disease (SD) and remission the treatment is to be continued as long as the treatment response lasts. At present four patients with recurrent carcinoma corpus uteri have been included. Dose level of toremifene is 200 mg per day. At 12 weeks one of the patients has partial remission (PR), two have SD and one progressive disease (PD). There have been no unacceptable side effects.</p></div>","PeriodicalId":17138,"journal":{"name":"Journal of steroid biochemistry","volume":"36 3","pages":"Page 241"},"PeriodicalIF":0.0000,"publicationDate":"1990-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0022-4731(90)90017-M","citationCount":"1","resultStr":"{\"title\":\"A phase II study of toremifene in carcinoma corporis uteri. Preliminary communication\",\"authors\":\"G. Horváth, C. Tropé, H.-E. Almbo\",\"doi\":\"10.1016/0022-4731(90)90017-M\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>A phase II study of toremifene was started in patients suffering from advanced carcinoma corporis uteri. Minimum duration of treatment was 3 months but with stabilized disease (SD) and remission the treatment is to be continued as long as the treatment response lasts. At present four patients with recurrent carcinoma corpus uteri have been included. Dose level of toremifene is 200 mg per day. At 12 weeks one of the patients has partial remission (PR), two have SD and one progressive disease (PD). There have been no unacceptable side effects.</p></div>\",\"PeriodicalId\":17138,\"journal\":{\"name\":\"Journal of steroid biochemistry\",\"volume\":\"36 3\",\"pages\":\"Page 241\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1990-06-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0022-4731(90)90017-M\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of steroid biochemistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/002247319090017M\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of steroid biochemistry","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/002247319090017M","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A phase II study of toremifene in carcinoma corporis uteri. Preliminary communication
A phase II study of toremifene was started in patients suffering from advanced carcinoma corporis uteri. Minimum duration of treatment was 3 months but with stabilized disease (SD) and remission the treatment is to be continued as long as the treatment response lasts. At present four patients with recurrent carcinoma corpus uteri have been included. Dose level of toremifene is 200 mg per day. At 12 weeks one of the patients has partial remission (PR), two have SD and one progressive disease (PD). There have been no unacceptable side effects.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
